Covidien and Mallinckrodt to Present at Deutsche Bank Conference


Covidien and Mallinckrodt to Present at Deutsche Bank Conference

MANSFIELD, Mass.--(BUSINESS WIRE)-- Covidien (NYS: COV) , a leading global provider of healthcare products, will present at the Deutsche Bank 38th Annual Health Care Conference in Boston on Wednesday and Thursday, May 29 and 30, 2013.

José E. Almeida, Chairman, President and Chief Executive Officer, will represent the Company in a session scheduled for May 30, 2013, at 12:00 p.m. ET.

Mark Trudeau, President, Pharmaceuticals, will discuss Mallinckrodt, the pharmaceuticals business of Covidien, in a session on May 29, 2013, scheduled to begin at 10:40 a.m. ET.

A live audio webcast of the presentations can be accessed at Covidien's Investor Relations website:


Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in three segments: Medical Devices, Pharmaceuticals and Medical Supplies. With 2012 revenue of $11.9 billion, Covidien has 43,000 employees worldwide in 70 countries, and its products are sold in over 140 countries. Please visit to learn more about our business.

Jacqueline Strayer, 508-261-8305
Senior Vice President
Corporate Communications
Bruce Farmer, 508-452-4372
Vice President
Public Relations
Coleman Lannum, CFA, 508-452-4343
Vice President
Investor Relations
Todd Carpenter, 508-452-4363
Senior Director
Investor Relations

KEYWORDS: United States North America Massachusetts


The article Covidien and Mallinckrodt to Present at Deutsche Bank Conference originally appeared on

Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.